Now with $18 million in hand from a trio of blue chip investors, Good Start Genetics is off to, well, a good start as it readies its panel of preconception genetic disease screening tests for launch into the in vitro fertilization market next year. But ultimately, its goal is clearly to leverage beyond the first set of tests and market.
Now with $18 million in hand from a trio of blue chip investors, Good Start Genetics Inc. is off to, well, a good start as it readies its panel of preconception genetic disease screening tests for launch into the in vitro fertilization market next year.
"I think this is the first company that's going to industrialize sequencing for clinical diagnostics," says Gary Kurtzman, MD, VP...
Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.
Thermo Fisher is aggressively managing its supply chain and cost base using its Practical Process Improvement (PPI) Business System. The company is also increasing investments in US-based manufacturing and R&D, with around $2bn allocated to bolster domestic operations.
FDA moves forward with implementing previous draft guidance and will consolidate forms, but the agency estimates limited impact in the total reporting burden.
